IGFBP7 has multiple binding partners, including structural ECM components, cytokines, chemokines, as well as several receptors ... including insulin-like growth factor binding protein-related protein ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Ratings ...

(Nasdaq: RZLT) ("Rezolute” or the "Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced ...

Open-label arm (infant participants DMC approved enrollment of infants into the double-blind portion of the study sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming ...

Peptides have gained significant attention in research due to their possible role in regulating various physiological ...

Anorexia nervosa (AN) is classically defined as a condition in which an abnormally low body weight is associated with an intense fear of gaining weight and distorted cognitions regarding weight, shape ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...